India Pharma Outlook Team | Friday, 18 September 2026
Parents and clinicians keep asking this question as clinics continue to promote the therapy.
Official reviews in India find that available evidence does not support stem cell therapy over behavioral and supportive approaches for Autism Spectrum Disorder.
The Union Health Ministry and Supreme Court therefore treat the intervention as unproven for routine use.
They restrict it to approved clinical trials rather than allow commercial offerings. This stance protects patients while leaving space for rigorous research that could one day change the picture.
An ICMR review examined the existing body of work and concluded that available evidence does not support stem cell therapy as superior to established behavioral and supportive therapies for ASD. Clinics still offer the treatment commercially in many places, yet regulators point to this gap.
The therapy remains outside the list of approved indications that the Ministry of Health maintains for routine clinical care. Approved stem cell uses cover specific cancers and certain autoimmune conditions. Autism does not appear on that list.
The absence of strong, consistent data from well-controlled studies leaves the therapy in the experimental category. Regulators therefore refuse to green-light it as standard care.
Calling the therapy unproven rather than banning it entirely serves a deliberate purpose. The Supreme Court judgment in the Yash Charitable Trust case made this clear in January 2026.
The court held that patients have no fundamental or statutory right to demand experimental treatment outside the regulatory framework. At the same time, the judgment directed authorities to strengthen oversight and shift patients already receiving unverified therapies into legitimate clinical trials.
This approach keeps the door open for scientific progress. Approved clinical trials that follow the National Guidelines for Stem Cell Research, 2017, issued by ICMR and the Department of Biotechnology, can still proceed.
Researchers can generate the high-quality data that current reviews find missing. An outright ban would close that research pathway. Labeling the therapy unproven and confining it to trials balances patient safety with the need for better evidence.
Key points the advisory stresses:
Also Read: How Regulatory Readiness Can Shape Pharma's Global Growth
The Union Health Ministry issued its advisory on 16 September 2026 and directed states and Union Territories to enforce the existing framework. State and district regulators must ensure that government and private clinical establishments stop offering unapproved stem cell interventions as routine services.
The National Medical Commission reinforced the same message. Unauthorized administration, prescription, promotion or advertisement of stem cell therapy beyond approved indications now counts as professional misconduct. State Medical Councils must examine complaints and take disciplinary action when they establish violations.
Violations can also trigger penalties under the Clinical Establishments Act in states that have adopted it, including cancellation of registration. The message is consistent across agencies: science has not yet established stem cell therapy as an effective standard care for autism, so the therapy belongs only in controlled research settings until stronger evidence emerges.
.jpg)
